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Abstract 14 
The purpose of this study was to prepare cubosomes encapsulating the model antigen ovalbumin (OVA) via 15 
spray drying, and to characterise such cubosomes with a view for their potential application in oral vaccine 16 
delivery. Furthermore the cubosome formulation was loaded into polymeric microcontainers intended as 17 
an oral drug delivery system. The cubosomes consisted of commercial glyceryl monooleate, Dimodan®, 18 
containing OVA and were surrounded with a dextran shell prepared by spray drying. Cryo-TEM was used to 19 
confirm that cubosomes were formed after hydration of the spray dried precursor powder. The precursor 20 
powder had a mean particle size of 1.3±0.1 µm, whereas the mean diameter of the dispersed cubosomes 21 
was 282±7 nm (PDI: 0.18) measured by dynamic light scattering. 8.5±0.3 % (w/w) of OVA was present in the 22 
cubosome powder and OVA was found released slowly over the first 70 h, followed by a more rapid 23 
release. Total release of 47.9±2.8 % of loaded OVA occurred over 96 h in a buffer at pH 6.8.  When the 24 
powder was filled into microcontainers, and the opening covered with the pH sensitive polymer Eudragit 25 
S100, the pH sensitive ‘lid’ was intact at gastric pH, but release of OVA from the cubosomes and 26 
microcontainers occurred at pH 6.8, releasing 44.1±5.6 % of the OVA in 96 h. Small-angle X-ray scattering 27 
(SAXS) revealed that the ‘dry’ particles possessed an internal ordered lipid structure (lamellar and inverse 28 
micellar phase) by virtue of a small amount of residual water, and after hydration in buffer at pH 6.8, the 29 
particles formed the hexagonal inverse cubic phases, thereby indicating that cubosomes were formed 30 
when released from microcontainers.   31 
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Introduction 32 
Vaccination is often regarded as the most significant contribution to public health and disease prevention 33 
and moreover, it is a very cost-effective medical intervention [1,2]. Vaccination has reduced the morbidity 34 
and mortality resulting from diseases such as tuberculosis and smallpox and has thereby saved millions of 35 
lives. In spite of this, many infectious diseases remain endemic in large parts of the world, and therefore 36 
vaccination is an area in continuous development [1,2]. 37 
 38 
Most vaccines are administered by injection and there are only a few oral vaccines on the market such as 39 
rotavirus vaccine (as solution or suspension) and a capsule with vaccine formulation against typhoid fever 40 
[3]. Although, the oral route can be beneficial for vaccine administration [4,5].   Some of the advantages of 41 
oral vaccines are the ease of administration and an increased safety compared to injections. In addition, 42 
there is also a great potential for mass vaccination without the requirements of trained personnel [4,6]. 43 
Furthermore, oral vaccines have the ability to induce both mucosal and systemic immune responses [6,7], 44 
as shown in the 1990s with several HIV vaccines [8], and they are therefore considered ideal for combating 45 
infectious diseases. Although, oral vaccines have several attractive features, there are some major 46 
challenges.  47 
The target of vaccine formulations in the gastro-intestinal (GI) tract is the M-cells in the intestine [9]. The 48 
antigen might be damaged, when passing through the harsh environment of the GI tract, which in turn will 49 
lead to the need for large doses. In addition, there is a poor transport of the antigen across the intestinal 50 
epithelium [4]. 51 
 52 
Traditional vaccines are mainly composed of heat-inactivated bacteria or viruses resulting in high 53 
immunogenicity. The risk with these types of vaccines is that they, in the body, can change to the active 54 
state and thereby infect the patients with the bacteria or virus and thus, leading to unwanted side effects 55 
[1,10]. Consequently, new generation vaccines are developed with subunit antigens. These subunit 56 
antigens are highly purified components of pathogens and thereby chemically well-defined. Hence, there is 57 
a much higher safety than for traditional antigens, but as the subunit antigens lack most of the features of 58 
the original pathogen they tend to be poorly immunogenic [1,10]. Therefore, to succeed with oral vaccine 59 
delivery, delivery systems need to be developed, in which the antigen can be encapsulated into particles 60 
[11,12]. These particles will assure presentation of the antigen to the antigen-presenting cells, but can also 61 
stabilise and release the antigen over an extended period of time [10]. Some particles will provide an 62 
adjuvant effect in themselves, but potent adjuvants can in addition also be added to the particulates for 63 
inducing an effective immunity [13].  64 
 65 
There are many possibilities for vaccine delivery systems, and some of the most common ones are: 66 
polymeric micro- and nanoparticles, immunostimulatory complexes and liposomes [14,15]. Cubosomes 67 
have also shown to be an efficient delivery system for vaccines [11]. Cubosomes contain a highly twisted, 68 
continuous lipid bilayer with two congruent, non-intersecting water channels, giving the particles both 69 
hydrophobic and hydrophilic domains [11]. This offers great flexibility with respect to the types of 70 
compounds, that can be incorporated into the particles [16,17]. Rizwan et al. found that significantly higher 71 
amounts of antigen can be encapsulated in cubosomes compared to liposomes due to the larger surface 72 
area of cubosomes, and moreover in cubosomes, the antigen was also retained more efficiently compared 73 
to liposomes [11].  74 
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Traditionally, cubosomes are produced by mixing monoolein or phytantriol and water and thereby creating 75 
a high-energy dispersion followed by colloidal stabilisation using polymeric stabilisers [11,18,19]. However, 76 
it can be desirable to have the vaccine particles in a powder form (here termed “precursors”), and 77 
precursors of cubosomes have earlier been produced by either freeze drying [20] or spray drying [21–23]. 78 
In the spray drying process, dry powder precursors have the active ingredient incorporated, and upon 79 
hydration colloidally stable cubosomes are spontaneously formed. The powder form of the vaccine 80 
formulation can be advantageous in terms of stability of the antigen. Also, there is no need for a cold-chain 81 
storage which is needed for traditional vaccines [4].  82 
 83 
After oral administration of the vaccine formulations, the antigen needs to be protected in the stomach and 84 
during transportation to the small intestine. In the small intestine, the vaccine particles should be delivered 85 
to the microfold (M) cells of the peyer’s patches as they will present the antigen to the underlying immune 86 
cells and thereby obtain an immune response [24]. The particles, carrying the antigen (and adjuvant), can 87 
give some protection of the antigen through the GI environment, but often the particles will also degrade 88 
on the way to the intestine, and therefore more advanced drug delivery systems can be necessary. An 89 
example of these advanced drug delivery systems is microcontainers. Microcontainers are polymeric, 90 
cylindrical devices in the micrometre size range (Fig. 1) [25–27]. They have the potential for targeted 91 
and/or sustained delivery in the GI tract [28]. Some of the advantages of the microcontainers are that size 92 
and shape can be controlled very precisely. Furthermore, the devices allow for unidirectional release, as 93 
only one side of the microcontainer is open, compared to more conventional microparticles where release 94 
can occur from the whole surface area. This has shown to increase the drug concentration at the 95 
microdevice-cell interface and thereby, allowing for increased permeation of the drug in vitro leading to 96 
enlarged oral bioavailability of the drug [27,29,30]. In addition, the antigen can be protected inside the 97 
cavity of the microcontainer from the harsh environment of the stomach until release is desirable [31,32]. 98 
The microcontainers have previously shown to interact with the intestinal mucus resulting in prolonged 99 
drug absorption [27]. It is reported in the literature that one way to improve oral vaccine delivery is to 100 
extend the intestinal residence time [13], hence, the microcontainers can be a promising platform for this 101 
purpose. In this paper, SU-8 (an epoxy photoresist) was used as a model polymer for fabrication of the 102 
microcontainers [25,26,31], but microcontainers have also been fabricated using biopolymers such as poly-103 
L-lactic acid (PLLA) [33,34].  104 
 105 
The aim of this study was, as a proof-of-concept, to prepare and characterise cubosomes loaded with 106 
ovalbumin (OVA) in a spray dried powder form for future application in oral vaccine delivery. The precursor 107 
powder was filled into microcontainers for protection and release control, and the in vitro release was 108 
studied together with small-angle X-ray scattering (SAXS) to confirm whether cubosomes were released 109 
from the microcontainers as internally structured particles. 110 
 111 
 112 
Fig. 1: SEM image of an SU-8 microcontainer with an inner diameter of 223 µm [26].  113 
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 114 
Materials and methods 115 
Materials 116 
OVA was purchased from TCI Europe (Zwijndrecht, Belgium). Dimodan® D90 was kindly donated by Danisco 117 
(Grindsted, Denmark). Dextran (from Leuconostoc Mesenteroides) and potassium dihydrogen phosphate 118 
were acquired from Sigma-Aldrich (St. Louis, MO, USA). Pierce BCA Protein Assay kit was purchased from 119 
Thermo Fisher Scientific (Rockford, IL, USA). Deionised water was obtained from an SG Ultra Clear water 120 
system (SG Water USA, LLC, Nashua, NH, USA) and was freshly produced in all cases. All other chemicals 121 
used were of analytical grade.  122 
 123 
Spray drying of precursors for cubosomes containing OVA 124 
Cubosomes were prepared using a commercial source of glyceryl monooleate (GMO), Dimodan® MO 90/D. 125 
The cubosomes were loaded with OVA as a model antigen, and the particles were surrounded by a dextran 126 
shell. The particles were prepared by first dissolving GMO in ethanol (1.78 w/v %), and then mixing with a 127 
solution of OVA in MilliQ water (0.075 final w/w % of OVA). After 1 h of mixing, dextran dissolved in MilliQ 128 
water (1.77 w/v %) was added to the GMO/OVA solution (0.72 w/w % of GMO + OVA), and the final 129 
solution was spray dried using a B 290 Büchi mini spray dryer (Büchi Labortechnik AG, Flawil, Switzerland). 130 
Free OVA was not removed prior to the spray drying process. 131 
For the spray drying of the precursors, a 0.7-mm nozzle was used and air was utilised as the drying medium. 132 
Spray drying was performed at an inlet temperature of 200 °C resulting in an outlet temperature of 133 
approximately 85 °C. The drying flow rate was set to 32 m3/h and an aspirator capacity of 80 % with a feed 134 
rate of 4 mL/min was used. Particles without OVA were also produced as blank particles and used as 135 
reference.  136 
 137 
Cryo-TEM of cubosomes 138 
The precursors for the cubosomes with OVA were dispersed in MilliQ water at a concentration of 1 mg/mL. 139 
The samples for the Cryo-TEM studies were prepared in a controlled environment vitrification system 140 
(CEVS). A small amount of the sample (5 μL) was put on a carbon film supported by a copper grid and 141 
blotted with filter paper to obtain a thin liquid film on the grid. The grid was quenched in liquid ethane at 142 
−180 °C and transferred to liquid nitrogen (−196 °C). The samples were then examined using a Tecnai G2 143 
F30 Transmission Electron Microscope (FEI, Eindhoven, The Netherlands) operating at a voltage of 300 kV 144 
and a working temperature of −180 °C. Images were recorded using Gatan UltraScan 1000 (2k × 2k) CCD 145 
camera (Gatan, California, USA).  146 
 147 
Size of particles  148 
The size of the dry particles with the dextran shell was measured using aerosizer particle size analyser 149 
(Model 3321, TSI Incorporated, MN, USA) by setting the pump to 1.37 bar and with a capillary flow of 8 150 
L/min. A small amount of powder was distributed on the plate and the particle size was measured in six 151 
replicates.  152 
 153 
For the particles dispersed in water, the particle size distribution (Z-average), polydispersity (PDI) and zeta 154 
potential were determined using dynamic light scattering (Malvern Zetasizer, NanoZs ZEN 3600, Malvern, 155 
UK). Measurements were performed at 37°C, and the results presented are the mean of three successive 156 
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measurements of 100 s of at least three independent samples. Samples were diluted with water to adjust 157 
the signal level.  158 
 159 
OVA present in the cubosomes  160 
Precursor powder (10 mg) was added to a solution of 20 mM phosphate buffer, pH 6.8 containing 5 % 161 
Triton X-100. After vortex mixing, the cubosomes were dissolved and a sample of 200 µL was taken out. A 162 
BCA Protein Assay kit was used to determine how much OVA was present in the cubosome powder by 163 
following the procedures for the standards and samples recommended by the manufacturer. The same 164 
process was performed with the blank cubosomes to check for any cross activity of the formulation.  The 165 
absorbance was measured at 562 nm on a plate reader, and the obtained absorbance values were analysed 166 
against the standard curves prepared on the same day as the samples. OVA entrapment was then 167 
determined by calculating the difference between the total OVA added before the spray drying process and 168 
the free fraction of OVA in the solution. The experiments were performed in triplicates.  169 
 170 
Fabrication of SU-8 microcontainers 171 
Production of the microcontainers involved two steps of photolithography with the negative epoxy-based 172 
photoresist, SU-8 [26,32]. The microcontainers were structured on a fluorocarbon coating deposited on top 173 
of the supporting silicon wafer by plasma polymerisation. This enabled dry removal of the fabricated SU-8 174 
devices from the support substrate in order to obtain individual microcontainers if needed [27,35]. The 175 
fabricated microcontainers had an inner diameter of 223±3 µm and a height of 270±3 µm (mean±SD, n=6). 176 
Silicon wafers supporting the microcontainers were finally cut into squares of 12.8 x 12.8 mm2 using an 177 
Automatic Dicing Saw from DISCO (Kirchheim b. München, Germany). Each chip contained arrays of 25 x 25 178 
containers with a pitch of 450 µm.  179 
 180 
Filling of microcontainers with powder precursors 181 
Powder precursors were manually distributed on the microcontainer chip. The excess drug in between the 182 
microcontainers was then removed with pressurised air, resulting in powder-filled microcontainers [27]. 183 
The chip with microcontainers was weighed before and after filling to determine the amount of drug filled 184 
into the microcontainers.  185 
 186 
Spray coating of the filled microcontainers with Eudragit S100 187 
A spray coating system (ExactaCoat, Sono Tek, USA) equipped with an ultrasonic nozzle actuated at 120 kHz 188 
[36] was used to deposit Eudragit S100 (dissolved to a 2 % (w/w) solution in isopropyl alcohol) on the cavity 189 
of the drug-filled microcontainers in a set-up similar to previously described [33]. The generator power was 190 
set to 1.5 W, and the polymer solution was pumped through the nozzle at a flow rate of 100 µL/min. 191 
Nitrogen gas at a pressure of 10 mbar was used to direct the beam of droplets onto the microcontainers, 192 
and the distance between nozzle and substrate was 40 mm with the beam diameter on the substrate being 193 
approximately 4 mm. The lateral movements of the nozzle were controlled by an x-y stage and the nozzle 194 
path was defined in the equipment software. The nozzle was moved line-by-line at a speed of 25 mm/s, and 195 
the coating was repeated 60 times to obtain a coating thickness in the µm range.  196 
 197 
Release of OVA from the cubosomes 198 
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In vitro release of OVA from the cubosomes unconfined (bulk powder) and confined in microcontainers 199 
coated with Eudragit S100 was investigated on a µDISS profiler (pION INC, Woburn, MA). In both release 200 
studies, each channel was calibrated with its own OVA standard curve prior to the experiments. For the 201 
calibration curves, aliquots of OVA in water stock solution were repeatedly added to 10 mL of either a HCl 202 
solution or a phosphate buffer in order to achieve a range of defined standard concentrations, and the UV 203 
spectrum of each standard was recorded. The release experiments were performed at 37±0.5°C using a 204 
stirring rate of 200±5 rpm using 20 mm path length in situ UV probes on a µDISS profiler. The absorbance 205 
data was evaluated using 280 nm on the standard curve and utilising the 2nd derivative function in the Au 206 
Pro software affiliated with the µDISS profiler.  207 
 208 
The release of OVA from the precursor powder was studied in 20 mM phosphate buffer, pH 6.8 for 96 h. 209 
The in situ UV probes were situated in each sample vial containing 10 mg of powder and 10 mL of 210 
phosphate buffer was added. The probes scanned and detected the absorbance of released OVA. 211 
The release studies from the microcontainers were performed in a set-up similar to one previously 212 
described [25,27,33]. The chips with microcontainers were attached to cylindrical magnetic stirring bars 213 
(using carbon pads) and placed in the bottom of sample vials. The chips were covered with 10 mL of 0.1 M 214 
HCl pH 1.6 for 2 h and subsequently, the medium was changed to 10 mL of 20 mM phosphate buffer, pH 215 
6.8 for 96 h, and the in situ UV probes detected the absorbance.  216 
Both sets of experiments were performed in 3 replicates. 217 
 218 
Scanning electron microscopy of the microcontainers 219 
SEM was utilised to examine the microcontainers after filling, after spray coating of the lid of Eudragit S-220 
100, and after release in phosphate buffer at pH 6.8. The examinations were carried out using a Phenom 221 
Pro scanning electron microscope (Phenom World, Eindhoven, the Netherlands). Prior to the investigations, 222 
the microcontainer chip was mounted onto metal stubs, and imaging was performed at an operation 223 
voltage of 10kV with a 600x magnification.   224 
 225 
SAXS determination of the structure of cubosomes loaded into microcontainers 226 
The SAXS/WAXS beamline at the Australian Synchrotron, Clayton, Australia [37] was used to determine the 227 
internal structure of the spray dried particles, when the cubosomes were confined in microcontainers and 228 
released from the devices. The X-ray beam had an energy of 11 keV, and the 2D SAXS patterns were 229 
collected using a Pilatus 1M camera (active area 169 x 179 mm2 with a pixel size of 172 x 172 m), which 230 
was located 900 mm from the sample position. The total q range for the instrument configuration outlined 231 
above was 0.02 ˂ q ˂ 1.06 Å−1, and 2D SAXS patterns were collected for 1 sec. The in-house designed 232 
computer software ‘ScatterBrain’ was used to acquire and reduce these 2D patterns to 1D intensity versus 233 
q profiles. The powder-filled microcontainers were separated from the base using a scalpel, and filled into a 234 
1.5 mL capillary and SAXS patterns were acquired in dry state followed by addition of 50 µL of MilliQ water, 235 
where after patterns were acquired for a time period of 80 min. The set-up with empty microcontainers as 236 
an example can be seen in Fig. 2A, with an image of the microcontainers in a capillary in the X-ray beam 237 
shown in Fig. 2B.  238 
 239 
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       240 
Fig. 2: A) Schematic of the SU-8 microcontainers filled into a capillary to be used in the SAXS/WAXS 241 
synchrotron. B)  Micrograph showing the set-up with the microcontainers in the x-ray beam.  242 
 243 
Statistics  244 
The data are expressed as mean ± standard deviation (SD). Where appropriate, statistical analysis was 245 
carried out using Student t-tests using GraphPad Prism version 7.00 (GraphPad Software Inc., CA, USA). P-246 
values below 5 % (p < 0.05) were considered statistically significant. 247 
 248 
Results and discussion 249 
For the production of the powder precursors of cubosomes, spray drying was chosen as this is a simple 250 
technique converting a solution to powder in a one-step process [38]. GMO has for many years been one of 251 
the lipids of choice for producing cubosomes, as it is non-toxic, biocompatible and biodegradable [39], and 252 
therefore it was decided to produce GMO particles in this study. The spray drying technique is convenient 253 
for producing the powder precursors, but GMO can be challenging to spray dry as it immediately forms the 254 
cubic phase upon hydration. Spicer et al. studied the effect of applying ethanol as a hydrotrope and this 255 
resulted in the formation of a low-viscous emulsion that was easily spray dried [21]. For this reason, in this 256 
study, GMO was first dissolved in ethanol and then added to the aqueous dextran solution. It has been 257 
reported that GMO itself produces sticky agglomerates after spray drying, and to obtain a more flowable 258 
powder an aqueous starch or a dextran solution can be added prior to spray drying resulting in the GMO 259 
being encapsulated in a dry starch or dextran shell [21–23]. In this work, it was chosen to add dextran as 260 
the anti-cohesion agent, and the produced powder was flowable and easy to hydrate. After production of 261 
the GMO powder precursors, the powder was hydrated and cryo-TEM was performed to identify whether 262 
cubosomes were obtained. It can be observed in Fig. 3 that cubic structures were found after hydration of 263 
the powder.  264 
 265 
A)
B)
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 266 
Fig. 3: Cryo-TEM image of a representative hydrated particle with a distinct cubic liquid crystalline 267 
structure.  The resolution in cryo-TEM images is limited by the presence of dissolved dextran. 268 
 269 
In vitro characterisation of the particulates 270 
The size, shape and surface charge of a particulate vaccine carrier will influence its performance as a 271 
vaccine [40]. The dry powder with OVA and the dextran shell had a size of 1.3±0.1 µm, whereas the dry 272 
blank particles without OVA had a size of 1.6±0.1 µm. After hydration, self-assembled, close to neutrally 273 
charged nanoparticles were formed, with mean size of 146.1±1.3 nm and 281.7±7.4 nm for the blank and 274 
OVA-loaded particles, respectively (Table 1). There was a significant size difference between the blank and 275 
OVA-loaded particles (p-value ˂0.0001), and the PDI for both formulations was low, indicating 276 
homogeneous formulations. The particles were much smaller than those reported by Spicer et al., where 277 
the dry particles had a diameter of 24 μm, and in the hydrated form the cubosomes were in average 0.6 μm 278 
with a size distribution from 0.1 to 5 μm [22]. In general, it is reported that the particle size should be 279 
between 20 nm to 10 µm to be well recognised by the immune system [11], but more specifically for oral 280 
vaccine formulations, a size between 200-500 nm can be advantageous for uptake into the antigen-281 
presenting cells after oral administration [40,41]. In relation to this, it can be observed that the size of the 282 
cubosomes with OVA is in this size range, and the cubosomes should therefore be able to be taken up by 283 
the antigen-presenting cells.  284 
 285 
Table 1: Size measurements of the hydrated cubosomes with and without OVA dispersed in MilliQ water. 286 
The measurements were performed using dynamic light scattering in triplicates, and data are represented 287 
as mean±SD  288 
 Z-average (nm) PDI Zeta potential (mV) 
Blank particles 146.1 ± 1.3 0.15±0.02 -0.43±0.077 
Particles with OVA 281.7 ± 7.4 0.18±0.11 -0.18±0.042 
 289 
Presence and release of OVA in and from the particles  290 
Before the release measurements, it was initially determined that 8.5±0.3 % (w/w) OVA was present in the 291 
cubosome powder. It is also well-known that cubosomes often provide a sustained release of a drug [39], 292 
and this is also observed in this study, where release studies in buffer at pH 6.8 showed that during the first 293 
100 nm
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70 h, OVA was slowly released, followed by a more rapid release from 70-80 h. A total release of 47.9±2.8 % 294 
was observed in relation to the total loading of OVA in the cubosomes over a 96 h period (Fig. 4). It can be 295 
seen that there is a significant burst release of OVA from the cubosomes (insert in Fig. 4) of 18.2±1.6 % in 296 
the first 10 min. This is probably caused by the release of OVA from the powder just when the powder 297 
precursors are dispersed in the aqueous solution, and thereafter the OVA entrapped in the channels of the 298 
cubosomes is released. In the literature, it is reported that OVA was released during 168 h from cubosomes 299 
resulting in a complete release [18]. A study preparing precursors of cubosomes by spray drying, but 300 
encapsulating the highly lipophilic drug, efavirenz, also is reporting on a burst release of the drug of up to 301 
16 %, with a total release in 12 h of up to 56 %, again indicating that when dispersing powder precursors in 302 
aqueous solution a burst release is occurring [23]. A sustained release of OVA is also observed in this study 303 
and this could be beneficial when developing vaccine formulations [42].  304 
 305 
 306 
Fig. 4: Release of OVA from the cubosomes in 20 mM phosphate buffer pH 6.8, expressed as % of the total 307 
content of OVA. The insert is showing the release over the first 60 min. The release study was performed in 308 
triplicates, and the data represent mean±SD. 309 
 310 
Internal structure of particles formed upon hydration from microcontainers 311 
SAXS/WAXS can be used to detect phase transformations in self-assembled lipid systems, and this was 312 
utilised to identify whether particles released from the microcontainers contained internal nanostructures 313 
consistent with cubosomes. Fig. 5 shows the plot of intensity versus the scattering vector q obtained from 314 
the release of GMO particles in dry form and when the microcontainers containing the particles were 315 
dispersed in water for a period of 80 min. For the dry particles, it can be observed that there are three 316 
equally spaced peaks in the diffractogram (Fig. 5), indicating that the dry particles are in a lamellar phase 317 
with the lattice parameter of 49.5 Å (Table 2). There is also an inverse micellar phase present, indicated by 318 
the broad peak at q ~ 0,2 Å-1 in  the diffractogram) with a D-spacing of 31.1 Å. This can be explained by the 319 
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presence of residual moisture in the spray dried powder. According to the phase diagram of GMO in water, 320 
the inverse micellar phase and lamellar phase coexist at approximately 5 % water [43,44], consistent with  321 
Spicer et al. reporting approximately 5 % (w/w) of moisture content in their spray dried cubosome powders 322 
[22].  323 
 324 
After hydration (here exemplified by the diffractogram at 50 min), the liquid crystalline nanostructured 325 
particles showed a mix of phases, with peak indexing indicating coexisting inverse hexagonal (H2) phase 326 
(peaks at √1 : √3 : √4), . Pn3m cubic phase (peaks at √2 : √3 : √4), and la3d cubic phase (peaks at √6 : √8). 327 
These three phases appear in the GMO + water phase diagram [44], and the calculated lattice parameters 328 
are listed in Table 2. The presence of H2 and Pn3m cubic phases for commercial GMO samples in water 329 
might be expected at full hydration, however the la3d cubic phase is only expected at less than full 330 
hydration o the lipid. Therefore it is proposed that the particles were not completely hydrated after 50 min, 331 
which is also supported by the fact that after 80 min the la3d phase appears even less prominent.  332 
 333 
 334 
Fig. 5: 2D SAXS patterns were collected from cubosomes confined in microcontainers and followed while 335 
the cubosomes were released from the microcontainers in MilliQ water. The cubosome filled 336 
microcontainers were enclosed in a glass capillary during hydration for up to 80 min. After 50 min of 337 
hydration the particles show a mix of phases with inverse hexagonal (H2) phase (peaks at √1 : √3 : √4), 338 
Pn3m cubic phase (peaks at √2 : √3 : √4), and la3d cubic phase (peaks at √6 : √8).     339 
 340 
 341 
 342 
Table 2: Phase structure and lattice parameters obtained from SAXS measurements of dry particles and 343 
particles released from microcontainers after hydration, here with an example after 50 min of hydration.  344 
√2
√6
√1
√3
√3 √4√8 √4
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 Lattice parameters (Å) 
 Dry particles Hydration for 50 min 
Lamellar phase, L 49.5  
Inverse micellar phase, L2 31.1  
Inverse hexagonal phase, H2  61.0 
Inverse bicontinuous cubic 
phase, Pn3m 
 84.6  
Inverse bicontinuous cubic 
phase, Ia3d 
 132.7 
 345 
Loading of precursors into the microcontainers and coating of the pH sensitive lid 346 
After successfully loading the cubosomes into the microcontainers (Fig. 6A), the cavity of the 347 
microcontainers was coated with Eudragit S100 (Fig. 6B) as this polymer will dissolve at a pH value of 348 
approximately 7 corresponding to the pH found in the small intestine around the M cells [9].  349 
 350 
 351 
Fig. 6: SEM images of A) a cubosome-filled microcontainer, B) a filled microcontainers with a lid of Eudragit 352 
S100, and C) an empty microcontainer after release study in phosphate buffer pH 6.8. 353 
 354 
Release of OVA loaded cubosomes from coated microcontainers 355 
The coating on the cavity of the microcontainers can prevent the release until the intestine [33], and a large 356 
dose (approximately 2 µg of powder) of the vaccine formulation can be loaded into the cavity of the 357 
microcontainers [27]. In the study, the cavity of the microcontainers was coated with the pH sensitive 358 
polymer Eudragit S100. The release of OVA from the cubosomes and microcontainers was first measured 359 
for 2 h in a pH value corresponding to the pH of the stomach (pH 1.6), and here, as expected, no release 360 
was observed due to the intact layer of the Eudragit lid (Fig. 7). After 2 h, the pH of the medium was 361 
changed to reflect that of the small intestine (pH 6.8). Fig. 7 shows that the release of OVA is occurring, and 362 
this indicate that the cubosomes are also released from the microcontainers as these are empty after the 363 
release studies (Fig. 6C).  The release is appearing in a more controlled fashion than observed from the 364 
unconfined powder cubosomes (Fig. 4). The OVA release in pH 6.8 is 44.1±5.6 % in relation to the amount 365 
of OVA in the particles. This is comparable to the release from the bulk powder being 47.9 % after 96 h (p-366 
value: 0.4311).  367 
In the literature, a rice-based oral vaccine has shown to be efficient as a delivery system as it can protect 368 
the antigen from enzymes in the stomach [7]. The microcontainers have the same feature and therefore, 369 
there is a promise for the microcontainers to work as an oral vaccine system as well. When delivering 370 
vaccines by the oral route, the delivery system should be able to present the vaccine formulation to the M 371 
cells followed by transport to the immune cells to create a response. It has been shown to be effective to 372 
100 µm100 µm 100 µm
A) B) C)
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keep the vaccine formulation inside a particle for a significant period of time [10,12], securing a slow 373 
release. Therefore the slow release that the microcontainers and the cubosomes provide can be a great 374 
advantage when delivering vaccines.  375 
 376 
 377 
Fig. 7: Release of OVA from the cubosomes, when the vaccine formulation was confined in microcontainers. 378 
The release of OVA is expressed as a % of the loaded OVA into the cubosomes. For the first 2 h the release 379 
was measured in pH 1.6 followed by pH of 6.8 for up to 98 h. The data is presented in triplicates as a 380 
mean±SD.  381 
 382 
Conclusion 383 
Powder precursors of cubosomes loaded with OVA have been produced by spray drying, and it was 384 
concluded that the precursors contained cubic structure in bulk as well as when released from 385 
microcontainers. The microcontainers coated with an Eudragit S100 lid can serve as an oral vaccine delivery 386 
system protecting the cubosomes through the GI tract until release occurs in the small intestine. For these 387 
produced cubosomes to be completely developed as an oral vaccine system, an adjuvant needs to be 388 
added to the particles to obtain the optimal effect of this system and further investigations are therefore 389 
also needed for fully develop this oral vaccine delivery system.   390 
 391 
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